<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971279</url>
  </required_header>
  <id_info>
    <org_study_id>hamaky2</org_study_id>
    <nct_id>NCT03971279</nct_id>
  </id_info>
  <brief_title>Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis</brief_title>
  <official_title>Long Term Efficacy of Dexamethasone Intravitreal Implant (Ozurdex®) in Treatment of Recurrent VKH Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VKH disease is a vision threatening condition.The investigators consider that ozurdex
      intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done.

      Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®);
      Allergan, Inc, Irvine, CA)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">November 22, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>2 years</time_frame>
    <description>Change in BCVA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>optical coherence tomography (OCT) foveal thickness</measure>
    <time_frame>2 years</time_frame>
    <description>changes in central foveal thickness</description>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Posterior Uveitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Ophthalmic implant</intervention_name>
    <description>intravitreal injection of ozurdex implant</description>
    <other_name>ozurdex implant</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        16 patient with VKH disease who have recurrent attacks of posterio uveitis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent VKH posterior uveitis

        Exclusion Criteria:

          -  retinal pathology, other causes of posterior uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Elhamaky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha university faculty of medicine , INMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INMC</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>November 24, 2019</last_update_submitted>
  <last_update_submitted_qc>November 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Tarek Roshdy mohamed Mahgoub ELhamaky</investigator_full_name>
    <investigator_title>Lecturer of ophthalmology</investigator_title>
  </responsible_party>
  <keyword>dexamethasone;VKH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

